Development of Advanced Pharmacological Agents and Delivery Systems for the Treatment of Pterygium Drug Management
"Pterygium Drug" management refers to the pharmacological interventions used to prevent, treat, or mitigate the recurrence of pterygium—a triangular, benign growth of conjunctival tissue that extends onto the cornea. This condition is strongly associated with chronic exposure to ultraviolet (UV) light, dust, and dry conditions. While surgical excision is the definitive treatment for advanced cases that impair vision or cause significant irritation, pharmaceutical agents are essential both pre-operatively to reduce inflammation and, more crucially, post-operatively as an adjunctive therapy to prevent the high rate of tissue regrowth.
Current drug strategies post-surgery primarily focus on immunomodulation and inhibition of fibrovascular proliferation, the two main drivers of recurrence. Anti-inflammatory drugs, particularly topical corticosteroids, are used to suppress immediate post-operative inflammation. However, the long-term management of recurrence is often achieved using anti-metabolites, such as mitomycin C or 5-fluorouracil, which are applied intraoperatively or post-operatively to inhibit the proliferation of the fibroblasts responsible for the re-growth. The careful use of these agents is necessary due to potential ocular toxicity, necessitating precise dosing and application protocols.
Research is actively exploring novel, sustained-release drug delivery systems, such as biodegradable implants or specialized nanoparticles, to ensure a constant and localized therapeutic concentration on the ocular surface, minimizing systemic exposure and side effects. Furthermore, efforts are underway to develop less toxic, targeted agents that specifically interrupt the signaling pathways involved in angiogenesis (blood vessel formation) and fibrosis formation. The goal is to develop a pharmacological regimen that can reliably replace or significantly enhance surgical outcomes, offering patients a non-invasive or minimally invasive option for the long-term control of this common, sunlight-induced ocular surface disease.